View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Banco Bilbao Vizcaya Argentaria SA: 1 director

A director at Banco Bilbao Vizcaya Argentaria SA sold 19,116 shares at 20.000EUR and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...

Oscar Rodriguez
  • Oscar Rodriguez

ACERINOX: FY2025 RESULTS AND T.P. INCREASE (ANÁLISIS BANCO SABADELL)

4Q'25 vs. 4Q'24 Results Sales: € 1.31 Bn (-1.3% vs. -24.1% BS(e) and -18.8% consensus); EBITDA: € 32 M (-78.7% vs. +116.6% BS(e) and +80.2% consensus); EBIT: € -23 M (116 M in 4Q'24 vs. 10 M BS(e) and 17 M consensus); Net Profit: € -47 M (€ 63 M in 4Q’24 vs. -15 M BS(e) and 17 M consensus); 2025 vs. 2024 Results Sales: € 5.78 Bn (+6.8% vs. +8.4% BS(e) and +6.2% consensus); EBITDA: € 354 M (-29.2% vs. -23.6% BS(e) and -20.0% consensus); EBIT: € 153 M (-56.0% vs. -46.6% BS(e) and -44.5% consensus...

Rafael Bonardell
  • Rafael Bonardell

VISCOFAN: 4Q’25 RESULTS (ANÁLISIS BANCO SABADELL)

4Q'25 vs. 4Q'24 Results Sales: € 315.12 M (+3.1% vs. +0.1% BS(e) and +2.2% consensus); EBITDA: € 71.75 M (-9.1% vs. +0.7% BS(e) and -2.3% consensus). FY2025 vs. FY2024 Results Sales: € 1.252 Bn (+4.0% vs. +3.2% BS(e) and +3.8% consensus); EBITDA: € 289.99 M (+1.6% vs. +4.3% BS(e) and +3.5% consensus).

Andres Bolumburu
  • Andres Bolumburu

CELLNEX: FY2025 RESULTS (ANÁLISIS BANCO SABADELL)

4Q'25 vs. 4Q'24 Results Sales: € 1.058 Bn (+1.9% vs. -1.4% BS(e) and +1.0% consensus); EBITDA: € 881.0 M (+2.1% vs. +0.1% BS(e) and +1.0% consensus); FY2025 vs. FY2024 Results Sales: € 3.995 Bn (+1.4% vs. +0.5% BS(e) and +1.1% consensus); EBITDA: € 3.317 Bn (+2.1% vs. +1.5% BS(e) and +1.8% consensus); Net Profit: € -361.0 M (€ -28.0 M in FY2024);

James Ratzer
  • James Ratzer

Cellnex (Buy, €34, +8%) Q4 25: Highest organic tenancy growth for 7 y...

We think Cellnex’s organic tower demand is the highest it has been for 7 years. We see that alone as supportive for the Cellnex story.

Rafael Bonardell
  • Rafael Bonardell

AMADEUS: RDOS. 4T’25 Y CAMBIO DE P.O. A BAJO REVISIÓN (ANÁLISIS BANCO ...

Rdos. 4T'25 vs 4T'24: Ventas: 1.622 M euros (+5,2% vs +3,6% BS(e) y +4,3% consenso); EBITDA: 577,9 M euros (+9,3% vs +4,5% BS(e) y +5,9% consenso). Rdos. 2025 vs 2024: Ventas: 6.517 M euros (+6,1% vs +5,7% BS(e) y +5,9% consenso); EBITDA: 2.507 M euros (+7,4% vs +6,3% BS(e) y +6,6% consenso).

Andres Bolumburu
  • Andres Bolumburu

CELLNEX: RDOS. 2025 (ANÁLISIS BANCO SABADELL)

Rdos. 4T'25 vs 4T'24: Ventas: 1.058 M euros (+1,9% vs +1,4% BS(e) y +1,0% consenso); EBITDA: 881,0 M euros (+2,1% vs +0,1% BS(e) y +1,0% consenso). Rdos. 2025 vs 2024: Ventas: 3.995 M euros (+1,4% vs +1,2% BS(e) y +1,1% consenso); EBITDA: 3.317 M euros (+2,1% vs +1,5% BS(e) y +1,8% consenso); BDI: -361,0 M euros (-28,0 M euros en 2024).

Andres Bolumburu
  • Andres Bolumburu

ACCIONA: RDOS. 2025 (ANÁLISIS BANCO SABADELL)

Rdos. 2025 vs 2024: Ventas: 20.236 M euros (+5,5% vs +3,2% BS(e) y +4,4% consenso); EBITDA: 3.211 M euros (+30,8% vs +19,0% BS(e) y +16,0% consenso); EBIT: 1.862 M euros (+41,5%); BDI: 803,0 M euros (+90,3%).

Andres Bolumburu
  • Andres Bolumburu

ACCIONA ENERGÍA: RDOS. 2025 (ANÁLISIS BANCO SABADELL)

Rdos. 2025 vs 2024: Ventas: 2.925 M euros (-4,0% vs -5,0% BS(e) y -5,8% consenso); EBITDA: 1.546 M euros (+47,2% vs +48,6% BS(e) y +51,7% consenso); BDI: 655,0 M euros (+83,5%).

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch